The World Health Organisation (WHO) have previously stated that cases of Lupus have almost tripled over the past four decades, whilst the 50% ten-year survival rate has increased to 80-90%. Although this disease has no cure, with treatment the condition can improve especially when treated early.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs